HAVCR2 and cancer: Recently, it has been reported that the TIM-3 pathway is involved in disabling of anti-cancer immune surveillance, not only in human myeloid leukemia [102], but also in several human cancer cell lines of both solid and liquid tumors (such as brain, colorectal, kidney, blood/mast cell, liver, breast, prostate, lung and skin tumors) [103].